Literature DB >> 9045923

CD8 T cells from major histocompatibility complex class II-deficient mice respond vigorously to class II molecules in a primary mixed lymphocyte reaction.

T Shimizu1, S Takeda.   

Abstract

Mature CD4+ and CD8+ T cells are restricted by major histocompatibility complex (MHC) class II and class I molecules, respectively. In a primary mixed lymphocyte reaction (MLR), CD8+ T cells from C57BL/6 (B6) mice can respond to allo-class I molecules, but not allo-class II molecules. However, a significant fraction of CD8+ T cells from C57BL/6 class II-deficient (B6Aalpha-) mice violate this rule by responding vigorously in a MLR to class II molecules. The frequency of responding cells is approximately 50% of that of B6 CD8+ T cells responding to B6bm1 allo-class I molecules. This response requires neither appropriate co-receptor, i.e. CD4, nor exogenous lymphokines, indicating that interactions between the T cell receptors (TCR) and class II molecules are remarkably efficient. Since these CD8+ T cells are positively selected by class I molecules in the thymus of class II-deficient mice, these CD8+ T cells should interact with both classes of MHC molecules. The absence of thymic negative selection by class II molecules may result in the production of these CD8+ T cells. The data imply that a substantial fraction of CD4+CD8+ double-positive thymocytes in wild-type mice interacts with both classes of MHC molecules prior to thymic selection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9045923     DOI: 10.1002/eji.1830270222

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  6 in total

1.  Alloantigen specific deletion of primary human T cells by Fas ligand (CD95L)-transduced monocyte-derived killer-dendritic cells.

Authors:  Christian Schütz; Sabine Hoves; Dagmar Halbritter; Huang-Ge Zhang; John D Mountz; Martin Fleck
Journal:  Immunology       Date:  2011-02-22       Impact factor: 7.397

Review 2.  Responses against complex antigens in various models of CD4 T-cell deficiency: surprises from an anti-CD4 antibody transgenic mouse.

Authors:  Yifan Zhan; Lorena E Brown; Georgia Deliyannis; Shirley Seah; Odilia L Wijburg; Jason Price; Richard A Strugnell; Phillip J O'Connell; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

3.  Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms.

Authors:  Scott G Hansen; Jonah B Sacha; Colette M Hughes; Julia C Ford; Benjamin J Burwitz; Isabel Scholz; Roxanne M Gilbride; Matthew S Lewis; Awbrey N Gilliam; Abigail B Ventura; Daniel Malouli; Guangwu Xu; Rebecca Richards; Nathan Whizin; Jason S Reed; Katherine B Hammond; Miranda Fischer; John M Turner; Alfred W Legasse; Michael K Axthelm; Paul T Edlefsen; Jay A Nelson; Jeffrey D Lifson; Klaus Früh; Louis J Picker
Journal:  Science       Date:  2013-05-24       Impact factor: 47.728

4.  Antiviral CD8+ T Cells Restricted by Human Leukocyte Antigen Class II Exist during Natural HIV Infection and Exhibit Clonal Expansion.

Authors:  Srinika Ranasinghe; Pedro A Lamothe; Damien Z Soghoian; Samuel W Kazer; Michael B Cole; Alex K Shalek; Nir Yosef; R Brad Jones; Faith Donaghey; Chioma Nwonu; Priya Jani; Gina M Clayton; Frances Crawford; Janice White; Alana Montoya; Karen Power; Todd M Allen; Hendrik Streeck; Daniel E Kaufmann; Louis J Picker; John W Kappler; Bruce D Walker
Journal:  Immunity       Date:  2016-10-18       Impact factor: 31.745

5.  HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers.

Authors:  Tinashe E Nyanhete; Alyse L Frisbee; Todd Bradley; William J Faison; Elizabeth Robins; Tamika Payne; Stephanie A Freel; Sheetal Sawant; Kent J Weinhold; Kevin Wiehe; Barton F Haynes; Guido Ferrari; Qi-Jing Li; M Anthony Moody; Georgia D Tomaras
Journal:  Sci Rep       Date:  2019-07-15       Impact factor: 4.379

6.  Modulation of thymic selection by expression of an immediate-early gene, early growth response 1 (Egr-1).

Authors:  T Miyazaki; F A Lemonnier
Journal:  J Exp Med       Date:  1998-08-17       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.